Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000169169 | SCV000220400 | likely pathogenic | Deafness, autosomal recessive 1A | 2015-02-05 | criteria provided, single submitter | literature only | |
EGL Genetic Diagnostics, |
RCV000711350 | SCV000700277 | pathogenic | not provided | 2012-08-28 | criteria provided, single submitter | clinical testing | |
Laboratory for Molecular Medicine, |
RCV000609278 | SCV000710859 | pathogenic | Rare genetic deafness | 2016-11-30 | criteria provided, single submitter | clinical testing | The p.Val13fs variant in GJB2, also reported as c.35dupG or c.35insG, has been r eported in >5 individuals with hearing loss who were compound heterozygous for a second pathogenic variant in GJB2 (Estivill 1998, Huang 2014, Snoeckx 2005, Tsu kada 2010). It has been identified in 6/250260 of the total chromosomes in the genome Aggregation Database (http://gnomad.broadinstitute.org/, dbSNP rs39812381 4). This low frequency in the general population is consistent with the carrier frequency for autosomal recessive hearing loss. This variant is predicted to ca use a frameshift, which alters the protein?s amino acid sequence beginning at po sition 13 and leads to a premature termination codon 35 amino acids downstream. In summary, this variant meets criteria to be classified as pathogenic for autos omal recessive hearing loss based on the predicted impact to the protein and mul tiple previously reported affected compound heterozygotes. |
Athena Diagnostics Inc | RCV000711350 | SCV000841705 | pathogenic | not provided | 2017-10-17 | criteria provided, single submitter | clinical testing | |
Integrated Genetics/Laboratory Corporation of America | RCV000169169 | SCV000919430 | pathogenic | Deafness, autosomal recessive 1A | 2018-09-11 | criteria provided, single submitter | clinical testing | Variant summary: GJB2 c.35dupG (p.Val13CysfsX35) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. The variant allele was found at a frequency of 2.5e-05 in 244704 control chromosomes (gnomAD and publications). The variant, c.35dupG, has been reported in the literature in multiple individuals affected with Autosomal Recessive Non-Syndromic Hearing Loss (Dai_2009, Bazazzadegan_2012, Hjelm_2010, Rabionet_2000, DAndrea_2002, Godbole_2010, Usami_2012, Banjara_2015). These data indicate that the variant is very likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Two clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation and both classified the variant as pathogenic/likely pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. |
Clinical Molecular Genetics Laboratory, |
RCV000678861 | SCV000805054 | pathogenic | Hearing loss | 2009-01-22 | no assertion criteria provided | clinical testing | |
Genetic Testing Center for Deafness, |
RCV000169169 | SCV000902319 | pathogenic | Deafness, autosomal recessive 1A | 2019-02-26 | no assertion criteria provided | case-control |